ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, PhD, Co-Founder, President and CEO ...

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary ... worldwide," said Zhen Li, Ph.D., co-founder, president ...

AbbVie is paying ADARx Pharmaceuticals $335 million upfront ... according to CEO and co-founder Zhen Li, Ph.D. Together, the two companies can unlock “tremendous clinical and commercial ...

AbbVie and ADARx Pharmaceuticals have announced a multi-billion dollar ... ADARx’s co-founder, president and chief executive officer, Zhen Li, added that the collaboration “further validates the ...

AbbVie is entering a collaboration and license option deal with ADARx Pharmaceuticals to develop ... potential across multiple disease areas," Zhen Li, co-founder, president and CEO of ADARx ...

SAN DIEGO, July 30, 2024 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals ... and I am pleased to welcome him to ADARx,” said Zhen Li, PhD, Co-Founder, President and CEO of ADARx.

SAN DIEGO, Jan. 10, 2025 (GLOBE NEWSWIRE) -- ADARx Pharmaceuticals, Inc. (ADARx), a late-stage clinical biotechnology company developing next-generation RNA therapeutics, today announced that Zhen Li, ...

Collaboration to leverage AbbVie's expertise in biotherapeutic drug development and commercialization together with ADARx's proprietary RNA technology to advance next-generation siRNA therapies ...